Corcept's Phase 3 ROSELLA trial of relacorilant meets primary endpoint; PFS and OS improved significantly

CORCEPT THERAPEUTICS INC

30% risk reduction in PFS (HR 0.70, p=0.008); median PFS 6.5 vs 5.5 months for nab-paclitaxel alone.
Interim OS also positive: median OS 16.0 vs 11.5 months (HR 0.69, p=0.012).
Relacorilant well-tolerated; no new safety signals; safety comparable between groups.
Company expects to submit NDA in Q3 2025 and MAA shortly thereafter.
Trial enrolled 381 patients globally; biomarker selection not required.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.